Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Official title

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Study identification

NCT ID

NCT01810913

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 2, Phase 3

Lead sponsor

National Cancer Institute (NCI)

NIH

Enrollment

613 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Mar 21, 2013

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Last update posted

May 3, 2026

2013 – 2027

United States locations

U.S. sites

337

U.S. states

45

U.S. cities

269

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.